


Corporate **FACT SHEET**




Corporate Profile:

IntriCon Corporation (NASDAQ: IIN), a medical device company based in Arden Hills, MN, is committed to enhancing the mobility and effectiveness of body-worn devices that connect people to people and to devices around them. IntriCon serves the body-worn device market by designing, developing, engineering, distributing and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for medical bio-telemetry devices, value hearing health, professional audio communication devices. Over the past several years, IntriCon has increased investments in the continued development of four critical core technologies: Ultra-Low-Power Digital Signal Processing, Ultra-Low-Power Wireless, Microminiaturization, and Miniature Transducers. These four core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable more advanced devices. IntriCon is focused on three key markets: medical, value based hearing healthcare, and professional audio communications. Utilizing this expertise IntriCon is moving to: improve margins by actively increasing the percentage of proprietary content; increase core business revenue and margins by maximizing product research and development; strengthen its leadership position in the body-worn device market by pursuing merger and acquisition opportunities. More information about the company and its products can be found at www.intricon.com.

Revenue & EPS (continuing operations) Quarterly Trends




TTM Revenue by Market from continuing operations



Stock Performance:

IIN (COMMON STOCK)	
Exchange	NASDAQ GM (US Dollar)
Price	\$9.10
Volume Change	(5%)
Volume	21,300
52 Week Range	\$4.12 - \$9.15
Market Cap	\$62,212
EPS from Continuing Rolling Operations (\$0.50)	
PE Ratio	N/A
Shares Outstanding	6,836,455



Data as of 3/31/2017

For more up-to-date stock performance information, visit our investor relations section of our website. www.intricon.com.

Investor Contact:

SCOTT LONGVAL

Chief Financial Officer, Secretary & Treasurer

Phone 651-604-9526

slongval@intricon.com

Recent Events:

February 17, 2017

On February 17, 2017, the Company completed the sale of the assets of its cardiac diagnostic monitoring business to Datrix, LLC. IntriCon made the strategic decision to divest its non-core CDM business in order to focus financial and operational resources on value hearing health and the growing direct-to-consumer (DTC) opportunity. Terms of the transaction include a four year earn-out based on revenue thresholds.

January 19, 2017

The Company announced that it has exercised its option to acquire the remaining 80-percent stake in DeKalb, Ill.-based Hearing Help Express (HHE), a direct-to-consumer mail order hearing aid provider. Terms of the transaction include \$650,000 in cash, guaranty of HHE's \$2 million note and an earn-out. The deal is expected to close in the first half of 2017, subject to customary closing conditions. "Completing this acquisition will give IntriCon direct access to consumers and the emerging value-based hearing healthcare market," said Mark Gorder, president and chief executive officer of IntriCon. "HHE offers a lower-priced alternative for consumers to purchase devices directly—circumventing layers of costs associated with the conventional hearing aid channel. We look forward to building on the HHE platform by leveraging our own technically advanced devices and making targeted investments in management, marketing and advertising—and ultimately incorporating an online component."

Financial Update:

April 25, 2017

IntriCon Reports 2017 First-Quarter Results

For the 2017 first quarter, the company reported net sales of \$20.1 million, compared to \$18.1 million in the prior-year period. The increase was primarily due to year-over-year revenue gains from IntriCon's largest medical customer and included a \$1.4 million contribution from Hearing Help Express (HHE). Net sales rose 13 percent sequentially from the 2016 fourth quarter. IntriCon posted a net loss attributable to shareholders of (\$428,000), or (\$0.06) per share, versus net income attributable to shareholders of \$15,000, or \$0.00 per diluted share, for the 2016 first quarter. The 2017 first-quarter loss included a loss from discontinued operations of (\$277,000), or (\$0.04) per share, related to the divestiture of the company's CDM business. It also included non-recurring acquisition and redundancy expenses of approximately (\$230,000), or (\$0.03) per share.

Along with first-quarter results, the company also announced that it has entered into an agreement to acquire a 49 percent stake in Soundperience. Soundperience has designed state of the art self-fitting hearing aid technology. Soundperience software applications are the first psycho-acoustic way of analyzing peripheral hearing and central hearing processing. Headquartered in Frankfurt, Germany, Soundperience was founded by Andreas Perscheid, a long-time audiologist and entrepreneur. The company's self-fitting hearing aid technology is being used in the German market today, most notably through IntriCon's previously disclosed Signison joint venture with Soundperience. Currently, the technology is PC based and is wired to the hearing aid during programming. Said Gorder, "Incorporating self-fitting technology is a critical step in creating our high-quality, low-cost hearing healthcare ecosystem. We believe Soundperience's technology has the potential to drastically reduce the price of hearing aids, drive greater access and increase customer satisfaction. We anticipate piloting the cloud-based system, with our wireless hearing aids in the U.S. market via Hearing Help Express."

In summary, "As expected, we delivered strong top-line growth in the first quarter, which was driven by gains in medical and value hearing health," said Mark S. Gorder, president and chief executive officer of IntriCon. "Furthermore, we're making significant progress in establishing a new direct-to-consumer hearing aid distribution channel. Today's Soundperience agreement is another important milestone in that journey, and we continue to anticipate strong hearing health and medical performance in the second quarter."

Corporate Governance:

Mark S. Gorder	President, CEO & Founder
J. Scott Longval	CFO, Secretary & Treasurer
Mike Geraci	VP, Sales & Marketing
Dennis Gonsior	VP, Global Operations
Greg Gruenhagen	VP, Quality & Regulatory Affairs

Corporate Headquarters:

IntriCon Corporation
1260 Red Fox Road
Arden Hills, MN 55112
Tel: 651.636.9770
Fax: 651.636.9503
www.intricon.com